Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis

Gali Pariente¹ · Tom Leibson¹ · Talya Shulman¹ · Thomasin Adams-Webber² · Eran Barzilay³ · Irena Nulman¹

Published online: 17 May 2017
© Springer International Publishing Switzerland 2017

Erratum to: CNS Drugs DOI 10.1007/s40263-017-0433-0

An Online First version of this article was made available online at <http://link.springer.com/journal/40263/onlineFirst/page/1> on 22 April 2017. An error was subsequently identified in the article, and the following correction should be noted:

Page 1, abstract, column 2, lines 2–6: The following sentence, which previously read:

“... in utero exposure to lamotrigine monotherapy was found to be associated with significantly decreased rates of inborn defects (odds ratio [OR] 1.15; 95% confidence interval [CI] 0.62–2.16 and OR 1.25; 95% CI 0.89–1.74, respectively).” should read:

“... in utero exposure to lamotrigine monotherapy was not found to be associated with significantly increased rates of inborn defects (odds ratio [OR] 1.15; 95% confidence interval [CI] 0.62–2.16 and OR 1.25; 95% CI 0.89–1.74, respectively).”

The online version of the original article can be found under doi:[10.1007/s40263-017-0433-0](https://doi.org/10.1007/s40263-017-0433-0).

✉ Gali Pariente
galipa@bgu.ac.il

- ¹ Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada
- ² Hospital Library, The Hospital for Sick Children, Toronto, ON, Canada
- ³ Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel